Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Burlingame, California, specializing in the development of innovative immuno-oncology therapies targeting multiple cancers. The company is advancing a robust pipeline of proprietary drug candidates designed to optimize immune system responses and enhance patient outcomes through precision medicine. By fostering strategic partnerships and leveraging cutting-edge research, Corvus is actively contributing to the transformation of cancer treatment, positioning itself as a key player in the evolving oncology landscape.